What's new

Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 9, Status: Authorised

Apr 11, 2025 - 16:26
 0
Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 9, Status: Authorised
Read More

Tags:

Previous Article

Bill to undo Biden-era water heater efficiency rule heads to Trump’s desk

Next Article

The D Brief: New CJCS; Contracts, cancelled; Europe pledges Ukraine aid; Report:...

Related Posts

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 17, 2025  0

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Highlight report - 13th Industry stakeholder platform o...

Apr 4, 2025  0